Refine by
Mtoz Biolabs Clinics Case Study Services
5 services found
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Biosimilars are biological products that are highly similar to an approved original biological drug (reference or brand drug) without any clinically meaningful differences in quality, safety, or efficacy compared to those approved. Biosimilars typically enter the market after the patent protection period of the original drug has expired, providing a more cost-effective treatment ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Short chain fatty acids (SCFAs) are a subgroup of saturated aliphatic fatty acids containing 2-5 carbon atoms, with acetate (C2), propionate (C3), and butyrate (C4) being the most abundant. They are the final products of dietary fiber fermented by beneficial coliform bacteria. Humans lack enzymes capable of degrading large amounts of dietary fiber, which passes undigested through the upper ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Proteolysis targeting chimera (PROTAC) drugs offer a novel approach to disease treatment by leveraging the body's innate protein degradation pathways. In contrast to traditional small-molecule inhibitors, PROTAC drugs promote the degradation of specific proteins rather than directly inhibiting their function, thus mitigating or eliminating their role in disease progression. ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Humans are highly organized systems comprised of approximately 3.72×1013 cells of various types, which maintain proper organ function and normal cellular homeostasis. Despite significant and revolutionary discoveries in the field of cell biology, the heterogeneity of cells still requires further investigation. Single-cell RNA sequencing (scRNA-seq) has become the latest method for revealing the ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Antibody therapies leverage human immune system antibodies to treat diseases by targeting specific proteins on pathogens or abnormal cells with exceptional precision. The development of antibody therapies has evolved from early polyclonal sera to monoclonal antibodies, and now to genetically engineered antibodies, focusing on enhancing drug safety, effectiveness, and manufacturing ...